Literature DB >> 23058049

Cultivation of RPMI 2650 cells as an in-vitro model for human transmucosal nasal drug absorption studies: optimization of selected culture conditions.

Stephan Reichl1, Karin Becker.   

Abstract

OBJECTIVES: The kinetics of drug absorption for nasally administered drugs are often studied using excised mucosal tissue. To avoid the disadvantages of animal experiments, cellular in-vitro models have been established. This study describes the optimization of culture conditions for a model based on the RPMI 2650 cell line, and an evaluation of this model's value for drug absorption studies.
METHODS: The cells were cultured in two serum-free media, serum-reduced variants or minimum essential medium (MEM) containing 5-20% serum. Cell seeding efficiency and proliferation behavior were evaluated in addition to viability and attachment following cryopreservation and thawing. Cells were cultured on different filter inserts for varying cultivation times. The epithelial barrier properties were determined by measuring transepithelial electrical resistance (TEER). Permeability was assessed using marker substances. KEY
FINDINGS: Serum supplementation of medium was necessary for cultivation, whereas the serum concentration showed little impact on proliferation and attachment following cryopreservation. A pronounced dependence of TEER on medium and filter material was observed. An optimized model cultured with MEM containing 10% serum on polyethylene terephthalate exhibited permeability that was similar to excised nasal mucosa.
CONCLUSIONS: These data indicate that this model could be an appropriate alternative to excised mucosa for the in-vitro evaluation of nasal drug absorption.
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23058049     DOI: 10.1111/j.2042-7158.2012.01540.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  10 in total

Review 1.  Is RPMI 2650 a Suitable In Vitro Nasal Model for Drug Transport Studies?

Authors:  Clément Mercier; Nathalie Perek; Xavier Delavenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

2.  The characterization of the human nasal epithelial cell line RPMI 2650 under different culture conditions and their optimization for an appropriate in vitro nasal model.

Authors:  Mateja Erdani Kreft; Urška Dragin Jerman; Eva Lasič; Tea Lanišnik Rižner; Neli Hevir-Kene; Luka Peternel; Katja Kristan
Journal:  Pharm Res       Date:  2014-08-22       Impact factor: 4.200

3.  Antioxidative NAC-Loaded Silk Nanoparticles with Opening Mucosal Tight Junctions for Nasal Drug Delivery: An In Vitro and In Vivo Study.

Authors:  Tze-Wen Chung; Ting-Ya Wu; Zheng-Yu Siah; Der-Zen Liu
Journal:  Pharmaceutics       Date:  2022-06-17       Impact factor: 6.525

4.  Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions.

Authors:  Domizia Baldassi; Bettina Gabold; Olivia Merkel
Journal:  Adv Nanobiomed Res       Date:  2021-05-06

5.  Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones.

Authors:  Jakub Wojcieszak; Dariusz Andrzejczak; Agata Woldan-Tambor; Jolanta B Zawilska
Journal:  Neurotox Res       Date:  2016-06-13       Impact factor: 3.911

6.  Reconstituted human upper airway epithelium as 3-d in vitro model for nasal polyposis.

Authors:  Francisco de Borja Callejas; Asunción Martínez-Antón; Isam Alobid; Mireya Fuentes; Julio Cortijo; César Picado; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

7.  Human parainfluenza virus type 3 (HPIV3) induces production of IFNγ and RANTES in human nasal epithelial cells (HNECs).

Authors:  Anna Lewandowska-Polak; Małgorzata Brauncajs; Edyta Paradowska; Marzanna Jarzębska; Marcin Kurowski; Sylwia Moskwa; Zbigniew J Leśnikowski; Marek L Kowalski
Journal:  J Inflamm (Lond)       Date:  2015-02-21       Impact factor: 4.981

8.  Applicability of RPMI 2650 and Calu-3 Cell Models for Evaluation of Nasal Formulations.

Authors:  Nadica Sibinovska; Simon Žakelj; Jurij Trontelj; Katja Kristan
Journal:  Pharmaceutics       Date:  2022-02-06       Impact factor: 6.321

9.  Pre-referral intranasal artesunate powder for cerebral malaria: a proof-of-concept study.

Authors:  Anne-Lise Bienvenu; Stephane Picot; Yobouet Ines Kouakou; Aurelien Millet; Elodie Fromentin; Nathalie Hauchard; Gonçalo Farias; Maxime Fieux; Aurelie Coudert; Roukayatou Omorou; Ibrahim Bin Sa'id; Adeline Lavoignat; Guillaume Bonnot
Journal:  Malar J       Date:  2022-10-11       Impact factor: 3.469

10.  Effect of High, Medium, and Low Molecular Weight Hyaluronan on Inflammation and Oxidative Stress in an In Vitro Model of Human Nasal Epithelial Cells.

Authors:  Giusy Daniela Albano; Anna Bonanno; Luca Cavalieri; Eleonora Ingrassia; Caterina Di Sano; Liboria Siena; Loredana Riccobono; Rosalia Gagliardo; Mirella Profita
Journal:  Mediators Inflamm       Date:  2016-04-24       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.